Novo Nordisk has submitted a revised unsolicited proposal to acquire Metsera, offering $65.60 per share in cash, which equates to an approximate aggregated equity value of $7.6 billion and an enterprise value of about $7.1 billion. The proposal also includes contingent value rights for up to $20.65 per share in cash, dependent on the achievement of certain clinical and regulatory milestones, with a total potential value of up to $2.4 billion. Following a competitive process and further consideration, Novo Nordisk has stated it will not increase its offer for Metsera.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001137747-en) on November 08, 2025, and is solely responsible for the information contained therein.